NASDAQ · Biotechnology · USD

Jyong Biotech Ltd. (MENS) Stock Analysis

Jyong Biotech Ltd. (MENS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MENS

$2.39

+$0.12 (+5.29%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MENS with… →

MENS Key Statistics

As of Sep 4, 2026

Trading

Open: $2.32
Previous Close: $2.27
Day's Range: 2.28–2.44
52-Week Range: 1.43–67.00
Volume: 51.00K

Valuation

Market Cap: $181.71M
P/E Ratio: unprofitable
EPS (ttm): −0.06

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$4.67M
Profit margin: 0.00%
Shares Outstanding: 74.23M
1-Year Return: −95.66%

Dividend and dates

Earnings Date: November 12, 2026estimated
Avg Volume: 84.89K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MENS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	−39.49%
2025 (partial year)	−60.93%

As of September 4, 2026.

MENS Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$4.67M	—
2024	$0.00	−$3.02M	—
2023	$0.00	−$4.40M	—
2022	$0.00	−$6.63M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$2.61M	−$4.67M	—
2024	$0.00	—	−$2.06M	−$3.02M	—
2023	$0.00	—	−$2.80M	−$4.40M	—
2022	$0.00	—	−$2.83M	−$6.63M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MENS Valuation vs Biotechnology Median

Median of 656 stocks

Metric	MENS	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Jyong Biotech Ltd. (MENS) is capitalised at $181.71M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 27.

The most recent close on file for MENS is $2.39, dated September 4, 2026. That is +$0.12 (+5.29%) against the previous close. Over the past 52 weeks the price has ranged from $1.43 to $67.00. The latest close sits 67.13% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $4.67M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −0.06.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned −95.66%. Daily returns over the trailing 1 year annualize to a volatility of 163.91%.

Growth & Income

No dividend is on file for MENS.

2026 is still running; the price is −39.49% year to date.

Peer Comparison

Jyong Biotech Ltd. (MENS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Jyong Biotech Ltd.	MENS	$181.71M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Jyong Biotech Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Jyong Biotech Ltd.

Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.

Visit website →